Announcement of an Exempt Purchase

Vendor will provide Adstiladrin a gene therapy medication for bladder cancer treatment.

This purchase is exempt from the usual selection processes of the Procurement Code because the procurement expenditure is for medical supplies or medical services necessary for the delivery of care and treatment at medical, dental, or veterinary teaching facilities utilized by SIU or U of I (30 ILCS 500 / 1-13(b-5)) This gene therapy medication is necessary to provide treatment to UI Health bladder cancer patients. Without access to these types of gene therapy medications, the Hospital would not be able to offer proper patient care and would drive patients elsewhere and result in a loss of revenue to the Hospital.